Amyloid (Amyloid Fibrils)

Subscribe to Selected New Research on Amyloid

14144 relevant articles (236 outcomes, 985 trials/studies) found for this Bio-Agent

Description: A type of extracellularly deposited substance composed of an amyloid protein and additional components including HEPARAN SULFATE PROTEOGLYCAN; LAMININ; COLLAGEN TYPE IV; SERUM AMYLOID P-COMPONENT; and APOLIPOPROTEINS E which together form characteristic amyloid fibrils. The core of amyloid fibrils is formed by the stacking of overlapping beta-pleated sheet domains of the amyloid protein. There are many different amyloid proteins that have been found forming the core of the fibrils in vivo. However, amyloid can be formed from any protein that exposes beta-pleated strand conformations during unfolding or refolding. A common characteristic of amyloid is the ability to bind such dyes as CONGO RED and thioflavine.

Also Known As:

Amyloid Fibrils; Amyloid Proteins; Amyloid Substance; Fibrils, Amyloid; Proteins, Amyloid; Substance, Amyloid

Relationship Network

Bio-Agent Context: Research Results

Macromolecular Substances: 43

Multiprotein Complexes: 37

Amyloid: 14144

amylin: 530

pramlintide: 81

amyloid prealbumin: 17

amyloid fibril protein AL: 4

amyloid fibril protein AS-SAM: 4

synelfin: 3

amylinamide: 2

amylin (8-37): 1

amyloid fibril protein Nis: 1

amyloid fibril protein SKO-III: 1

amyloid protein BAN: 1

insulinoma amyloid polypeptide precursor: 1

pro-islet amyloid polypeptide: 1

senile amyloid fibril protein ASc(1): 1

(N-Me)I26-IAPP (N-Me)G24

amylin (20-29)

amylin-biotin

amyloid fibril protein Alambda (ESI)

amyloid fibril protein ASc2

amyloid fibril protein EPS

amyloid fibril protein Es492

amyloid fibril protein RS

amyloid fibril protein SAF

amyloid K

amyloid protein 758

amyloid protein ATK

Gly(42)- transthyretin

human amyloid AGel protein

human amyloid L

human amyloid protein AR

human amyloid protein GRA

human FLJ20513 protein

human transthyretin-related amyloid fibril protein

IAPP(20-29) peptide

islet amyloid polypeptide (8-37)

Amino Acids, Peptides, and Proteins

Proteins: 58433

Amyloid: 14144

Amyloid beta-Protein: 1286

Serum Amyloid A Protein: 919

amylin: 530

Serum Amyloid P-Component: 184

pramlintide: 81

amyloid prealbumin: 17

amyloid fibril protein AL: 4

amyloid fibril protein AS-SAM: 4

synelfin: 3

amylinamide: 2

amylin (8-37): 1

amyloid fibril protein Nis: 1

amyloid fibril protein SKO-III: 1

amyloid protein BAN: 1

insulinoma amyloid polypeptide precursor: 1

pro-islet amyloid polypeptide: 1

senile amyloid fibril protein ASc(1): 1

(N-Me)I26-IAPP (N-Me)G24

amylin (20-29)

amylin-biotin

amyloid fibril protein Alambda (ESI)

amyloid fibril protein ASc2

amyloid fibril protein EPS

amyloid fibril protein Es492

amyloid fibril protein RS

amyloid fibril protein SAF

amyloid K

amyloid protein 758

amyloid protein ATK

Gly(42)- transthyretin

human amyloid AGel protein

human amyloid L

human amyloid protein AR

human amyloid protein GRA

human FLJ20513 protein

human transthyretin-related amyloid fibril protein

IAPP(20-29) peptide

islet amyloid polypeptide (8-37)

Experts

1.	Masters, Colin L: 31 articles (10/2008 - 01/2002)
2.	Barnham, Kevin J: 18 articles (10/2008 - 01/2003)
3.	Bush, Ashley I: 18 articles (05/2008 - 05/2002)
4.	Holtzman, David M: 18 articles (02/2008 - 03/2002)
5.	Cappai, Roberto: 17 articles (05/2008 - 01/2002)
6.	Klunk, William E: 14 articles (07/2008 - 08/2002)
7.	Blennow, Kaj: 14 articles (05/2008 - 01/2002)
8.	Mathis, Chester A: 13 articles (07/2008 - 08/2002)
9.	Butterfield, D Allan: 13 articles (01/2008 - 06/2002)
10.	Smith, Mark A: 13 articles (12/2007 - 05/2002)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 07/01/2006 - "Most drug discovery efforts for Alzheimer's disease (AD) have focused on prevention or clearance of beta-amyloid (Abeta) fibrils or oligomers, with far less attention to prevention of tau abnormalities that lead to neurofibrillary tangles (NFTs). " 01/01/2006 - "These results demonstrate that phase-contrast X-ray computed tomography is a highly sensitive imaging technique for analyzing dense-cored amyloid plaques in postmortem samples, and is beneficial in elucidating amyloid pathophysiology in Alzheimer's disease." 10/10/2003 - "Deposition of amyloid in the brain is important in the pathogenesis of Alzheimer's disease (AD), but it remains to be determined if deposition is due to increased production or decreased clearance of fibrillogenic forms of beta-amyloid (Abeta). " 09/01/2002 - "The identification of amyloid deposits in living Alzheimer disease (AD) patients is important for both early diagnosis and for monitoring the efficacy of newly developed anti-amyloid therapies. " 01/01/2008 - "Reducing the level of beta-amyloid accumulation in the brain could be beneficial for metabolic studies as well as potential therapeutic approach for prevention and treatment of Alzheimer's disease." Order ALL the reference details at left...
2.	Amyloidosis 07/31/1982 - "These observations support the view that major increases in SAA levels are a necessary condition for the deposition of this form of amyloid and suggest that prospective monitoring of the SAA concentration in predisposing diseases may help to identify those individuals who are most at risk for amyloidosis." 09/01/2003 - "Relapse occurred after 4 years of complete remission, and the second renal biopsy revealed amyloid light-chain (AL)-amyloidosis. " 12/01/1990 - "However, among 45 patients with biopsy-proven systemic amyloidosis (25, amyloid A type; 20, amyloid L type), 125I-SAP was cleared from the plasma more rapidly, accumulated in the amyloid deposits, and persisted there. " 12/01/2008 - "On the other hand, antioxidative intervention studies in animal models of AD-like amyloidosis show a significant reduction in amyloid beta deposition and behavioral improvements. " 09/01/2000 - "CONCLUSIONS: The serum HGF level was significantly elevated in both amyloid light-chain and amyloid A amyloidosis and was a very useful indicator of suspected amyloidosis as well as a potential prognostic indicator. " Order ALL the reference details at left...
3.	Inflammation 09/25/2008 - "This paper will give an overview on the protective effects of HupA, which includes regulating beta-amyloid precursor protein (APP) metabolism, protecting against Abeta-mediated oxidative stress, apoptosis and mitochondrial dysfunction, as well as anti-inflammation. " 06/01/1993 - "Prospective monitoring studies in patients whose JRA-associated inflammatory activity was in remission demonstrated regression of amyloid in 8 patients and no substantial changes in 8 others; however, in 4 further patients with active inflammation, there was accumulation of amyloid. " 05/01/2008 - "Overexpression of hNEP for 4 months in young APP/DeltaPS1 double-transgenic mice resulted in reduction in Abeta peptide levels, attenuation of amyloid load, oxidative stress, and inflammation, and improved spatial orientation. " 10/01/2000 - "There are two pathological defects in AD: chronic inflammation and impaired clearance of amyloid beta-peptide (Abeta). " 01/01/1988 - "In particular, the structure, synthesis and plasma clearance of the inflammation-associated amyloid precursor, SAA, have been extensively studied and the precursor-product relationship between circulating SAA, protein AA and fibrillar amyloid A clarified. " Order ALL the reference details at left...
4.	Dementia (Dementias) 09/01/2009 - "Amyloid imaging also shows significant promise in the differential diagnosis of mild cognitive impairment or atypical dementias. " 11/01/2006 - "Novel potential disease-modifying therapies now in preclinical research or clinical trials may be more effective in preventing or arresting the progressive dementia of AD and will provide a test of the amyloid hypothesis." 01/01/2006 - "Therefore, in addition to symptomatic treatment of dementia, therapeutic efforts are currently aimed at testing the efficacy of disease-modifying, anti-amyloid therapies. " 09/15/2009 - "Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study." 01/01/2009 - "Amyloid imaging studies support a model in which amyloid deposition is an early event on the path to dementia, beginning insidiously in cognitively normal individuals, and accompanied by subtle cognitive decline and functional and structural brain changes suggestive of incipient AD. " Order ALL the reference details at left...
5.	Nephrotic Syndrome (Syndrome, Nephrotic) 09/01/2003 - "Longterm complete remission of AL-amyloid-related nephrotic syndrome." 06/01/2000 - "Renal biopsy was repeated after 14 months, and, despite complete remission of nephrotic syndrome, no regression in amyloid deposition was found." 07/01/1994 - "The latter finding, and the remission of the nephrotic syndrome, provided strong evidence for regression of the amyloid deposits. " 01/01/1980 - "[Prolonged clinical remission (20 years) of amyloid nephrotic syndrome. " 07/01/2006 - "Biochemical testing and renal biopsy subsequently demonstrated nephrotic syndrome and amyloid deposition in association with myeloma. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Peptides
2.	Amyloid (Amyloid Fibrils)
3.	Antibodies
4.	Colchicine
5.	Proteins (Proteins, Gene)
6.	tau Proteins (tau Protein)
7.	Insulin (Novolin)
8.	Apolipoproteins E (ApoE)
9.	Amyloid Precursor Protein Secretases (beta-Secretase)
10.	peptide A

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Renal Dialysis (Hemodialysis)
4.	Therapeutics
5.	Transplants (Transplant)

Best Treatments:
Research Summary Report
on Alzheimer Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1032 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>